Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Albemarle Co. stock logo
ALB
Albemarle
$114.96
-0.3%
$122.90
$106.69
$247.44
$13.51B1.623.24 million shs1.42 million shs
The Hershey Company stock logo
HSY
Hershey
$187.17
-0.5%
$191.84
$178.82
$276.88
$38.37B0.341.51 million shs1.32 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$130.71
+2.9%
$126.34
$99.14
$133.10
$321.69B0.386.38 million shs12.75 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Albemarle Co. stock logo
ALB
Albemarle
-0.27%+2.85%-3.39%-4.07%-36.56%
The Hershey Company stock logo
HSY
Hershey
-0.52%+1.25%-1.98%-1.60%-28.49%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+2.91%+4.42%+4.12%+8.19%+15.23%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Albemarle Co. stock logo
ALB
Albemarle
4.9411 of 5 stars
4.23.04.20.62.61.73.1
The Hershey Company stock logo
HSY
Hershey
4.7941 of 5 stars
3.15.04.21.93.81.71.3
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.6578 of 5 stars
2.33.03.34.13.22.51.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Albemarle Co. stock logo
ALB
Albemarle
2.40
Hold$175.0552.27% Upside
The Hershey Company stock logo
HSY
Hershey
2.19
Hold$223.3319.32% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.58
Moderate Buy$131.250.41% Upside

Current Analyst Ratings

Latest MRK, HSY, and ALB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/19/2024
The Hershey Company stock logo
HSY
Hershey
Edward Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/18/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/17/2024
The Hershey Company stock logo
HSY
Hershey
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$205.00 ➝ $200.00
4/15/2024
The Hershey Company stock logo
HSY
Hershey
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$200.00 ➝ $179.00
4/11/2024
Albemarle Co. stock logo
ALB
Albemarle
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$135.00 ➝ $145.00
4/11/2024
Albemarle Co. stock logo
ALB
Albemarle
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$130.00 ➝ $160.00
4/11/2024
The Hershey Company stock logo
HSY
Hershey
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$213.00 ➝ $199.00
4/10/2024
Albemarle Co. stock logo
ALB
Albemarle
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$125.00 ➝ $135.00
4/10/2024
Albemarle Co. stock logo
ALB
Albemarle
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$137.00 ➝ $156.00
4/8/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$140.00 ➝ $143.00
4/5/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Albemarle Co. stock logo
ALB
Albemarle
$9.62B1.40$26.19 per share4.39$82.36 per share1.40
The Hershey Company stock logo
HSY
Hershey
$11.16B3.42$11.63 per share16.09$20.06 per share9.33
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.51$3.13 per share41.75$14.85 per share8.80

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Albemarle Co. stock logo
ALB
Albemarle
$1.57B$13.348.6216.542.1616.36%26.62%14.19%5/1/2024 (Confirmed)
The Hershey Company stock logo
HSY
Hershey
$1.86B$9.0520.6818.982.8916.67%51.79%16.96%5/3/2024 (Confirmed)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.14933.6413.221.650.61%9.33%3.61%5/28/2024 (Estimated)

Latest MRK, HSY, and ALB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/3/2024N/A
The Hershey Company stock logo
HSY
Hershey
$2.72N/A-$2.72N/AN/AN/A  
5/1/2024N/A
Albemarle Co. stock logo
ALB
Albemarle
$0.53N/A-$0.53N/AN/AN/A  
2/15/2024Q4 2023
Albemarle Co. stock logo
ALB
Albemarle
$0.99$1.85+$0.86$8.96$2.18 billion$2.36 billion    
2/8/2024Q4 2023
The Hershey Company stock logo
HSY
Hershey
$1.95$2.02+$0.07$2.34$2.72 billion$2.66 billion    
2/1/2024Q4 2023
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.09$0.03+$0.12$0.54$14.49 billion$14.63 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Albemarle Co. stock logo
ALB
Albemarle
$1.601.39%+1.28%11.99%29 Years
The Hershey Company stock logo
HSY
Hershey
$5.482.93%+12.21%60.55%15 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.36%+6.08%2,200.00%13 Years

Latest MRK, HSY, and ALB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/22/2024
Albemarle Co. stock logo
ALB
Albemarle
quarterly$0.401.35%3/14/20243/15/20244/1/2024
2/7/2024
The Hershey Company stock logo
HSY
Hershey
quarterly$1.372.82%2/16/20242/20/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Albemarle Co. stock logo
ALB
Albemarle
0.37
1.47
0.86
The Hershey Company stock logo
HSY
Hershey
0.92
0.97
0.52
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.89
1.25
1.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Albemarle Co. stock logo
ALB
Albemarle
92.87%
The Hershey Company stock logo
HSY
Hershey
57.96%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%

Insider Ownership

CompanyInsider Ownership
Albemarle Co. stock logo
ALB
Albemarle
0.38%
The Hershey Company stock logo
HSY
Hershey
0.34%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Albemarle Co. stock logo
ALB
Albemarle
9,000117.53 million117.08 millionOptionable
The Hershey Company stock logo
HSY
Hershey
20,505203.95 million203.26 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
72,0002.53 billion2.53 billionOptionable

MRK, HSY, and ALB Headlines

SourceHeadline
Bank Julius Baer & Co. Ltd Zurich Sells 1,166,230 Shares of Merck & Co., Inc. (NYSE:MRK)Bank Julius Baer & Co. Ltd Zurich Sells 1,166,230 Shares of Merck & Co., Inc. (NYSE:MRK)
marketbeat.com - April 25 at 8:21 PM
Merck & Co hikes 2024 guidance as Keytruda climb continuesMerck & Co hikes 2024 guidance as Keytruda climb continues
thepharmaletter.com - April 25 at 5:56 PM
Dow Earnings: How Merck, Caterpillar Shares Are FaringDow Earnings: How Merck, Caterpillar Shares Are Faring
schaeffersresearch.com - April 25 at 2:40 PM
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts SalesMerck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
zacks.com - April 25 at 1:11 PM
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual OutlookMerck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
benzinga.com - April 25 at 12:55 PM
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little PharmaHeard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma
finance.yahoo.com - April 25 at 12:55 PM
Mercks Cancer Drug and Vaccine Sales Drive Better-Than-Expected ResultsMerck's Cancer Drug and Vaccine Sales Drive Better-Than-Expected Results
investopedia.com - April 25 at 11:36 AM
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMerck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com - April 25 at 11:31 AM
Merck jumps on profit beat as Bristol Myers Squibb slips to a lossMerck jumps on profit beat as Bristol Myers Squibb slips to a loss
proactiveinvestors.com - April 25 at 9:51 AM
Merck & Co., Inc. (NYSE:MRK) Issues FY24 Earnings GuidanceMerck & Co., Inc. (NYSE:MRK) Issues FY24 Earnings Guidance
marketbeat.com - April 25 at 9:25 AM
Merck’s first-quarter results beat expectations amid healthy vaccine-sales growthMerck’s first-quarter results beat expectations amid healthy vaccine-sales growth
marketwatch.com - April 25 at 7:55 AM
Merck Lifts FY24 Outlook After Higher Q1 Earnings, Above Market; Stock Up In Pre-marketMerck Lifts FY24 Outlook After Higher Q1 Earnings, Above Market; Stock Up In Pre-market
markets.businessinsider.com - April 25 at 7:55 AM
Merck raises 2024 profit forecast on strong sales of cancer drug KeytrudaMerck raises 2024 profit forecast on strong sales of cancer drug Keytruda
finance.yahoo.com - April 25 at 7:55 AM
UPDATE 1-Merck raises 2024 profit forecast on strong sales of cancer drug KeytrudaUPDATE 1-Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
finance.yahoo.com - April 25 at 7:55 AM
Merck & Co., Inc. (NYSE:MRK) Releases FY 2024 Earnings GuidanceMerck & Co., Inc. (NYSE:MRK) Releases FY 2024 Earnings Guidance
marketbeat.com - April 25 at 7:24 AM
Merck raises 2024 profit forecast on strong cancer, HPV drugs salesMerck raises 2024 profit forecast on strong cancer, HPV drugs sales
reuters.com - April 25 at 6:33 AM
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine salesMerck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
cnbc.com - April 25 at 6:32 AM
Merck Announces First-Quarter 2024 Financial ResultsMerck Announces First-Quarter 2024 Financial Results
businesswire.com - April 25 at 6:30 AM
Poplar Forest Capital LLC Sells 98,453 Shares of Merck & Co., Inc. (NYSE:MRK)Poplar Forest Capital LLC Sells 98,453 Shares of Merck & Co., Inc. (NYSE:MRK)
marketbeat.com - April 24 at 11:57 PM
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
zacks.com - April 24 at 1:06 PM
Merck Q1 Earnings Preview: Strong quarter expectations on the back of core products growthMerck Q1 Earnings Preview: Strong quarter expectations on the back of core products' growth
msn.com - April 24 at 12:11 PM
4 Large Drug Stocks to Hold on to Amid Industry Challenges4 Large Drug Stocks to Hold on to Amid Industry Challenges
zacks.com - April 24 at 11:11 AM
Whats in Store for These 5 Pharma Bigwigs in Q1 Earnings?What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
zacks.com - April 24 at 10:21 AM
Brokers Offer Predictions for Merck & Co., Inc.s Q4 2025 Earnings (NYSE:MRK)Brokers Offer Predictions for Merck & Co., Inc.'s Q4 2025 Earnings (NYSE:MRK)
americanbankingnews.com - April 24 at 2:56 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Albemarle logo

Albemarle

NYSE:ALB
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Specialties segment provides bromine-based specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals; lithium specialties, such as butyllithium and lithium aluminum hydride; develops and manufactures cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for pyrotechnical applications that include airbag initiators. The Ketjen segment offers clean fuels technologies (CFT), which is composed of hydroprocessing catalysts (HPC) together with isomerization and akylation catalysts; fluidized catalytic cracking (FCC) catalysts and additives; and performance catalyst solutions (PCS), which is composed of organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.
Hershey logo

Hershey

NYSE:HSY
The Hershey Company, together with its subsidiaries, engages in the manufacture and sale of confectionery products and pantry items in the United States and internationally. The company operates through three segments: North America Confectionery, North America Salty Snacks, and International. It offers chocolate and non-chocolate confectionery products; gum and mint refreshment products, including mints, chewing gums, and bubble gums; protein bars; pantry items, such as baking ingredients, toppings, beverages, and sundae syrups; and snack items comprising spreads, bars, snack bites, mixes, popcorn, and pretzels. The company provides its products primarily under the Hershey's, Reese's, Kisses, Jolly Rancher, Almond Joy, Brookside, barkTHINS, Cadbury, Good & Plenty, Heath, Kit Kat, Payday, Rolo, Twizzlers, Whoppers, York, Ice Breakers, Breath Savers, Bubble Yum, Lily's, SkinnyPop, Pirates Booty, Dot's Homestyle Pretzels, and ONE Bar brands, as well as under the Pelon Pelo Rico, IO-IO, and Sofit brands. It markets and sells its products to wholesale distributors, chain grocery stores, mass merchandisers, chain drug stores, vending companies, wholesale clubs, convenience stores, dollar stores, concessionaires, and department stores. The company exports its products in approximately 80 countries worldwide. The Hershey Company was founded in 1894 and is headquartered in Hershey, Pennsylvania.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.